SE9904416D0 - Crystalline form - Google Patents

Crystalline form

Info

Publication number
SE9904416D0
SE9904416D0 SE9904416A SE9904416A SE9904416D0 SE 9904416 D0 SE9904416 D0 SE 9904416D0 SE 9904416 A SE9904416 A SE 9904416A SE 9904416 A SE9904416 A SE 9904416A SE 9904416 D0 SE9904416 D0 SE 9904416D0
Authority
SE
Sweden
Prior art keywords
crystalline form
pharmaceutically
compound
acceptable salt
solvate
Prior art date
Application number
SE9904416A
Other languages
Swedish (sv)
Inventor
Maria Boije
Original Assignee
Astra Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astra Ab filed Critical Astra Ab
Priority to SE9904416A priority Critical patent/SE9904416D0/en
Publication of SE9904416D0 publication Critical patent/SE9904416D0/en
Priority to US10/148,821 priority patent/US6531622B1/en
Priority to SK765-2002A priority patent/SK7652002A3/en
Priority to CNB008163804A priority patent/CN1198799C/en
Priority to IL14957700A priority patent/IL149577A0/en
Priority to UA2002053990A priority patent/UA75582C2/en
Priority to KR1020027007071A priority patent/KR20030029040A/en
Priority to JP2001541858A priority patent/JP2003515582A/en
Priority to CA002392038A priority patent/CA2392038A1/en
Priority to CZ20021902A priority patent/CZ20021902A3/en
Priority to SI200030350T priority patent/SI1237855T1/en
Priority to DK00983618T priority patent/DK1237855T3/en
Priority to RU2002113450/04A priority patent/RU2268880C2/en
Priority to EP00983618A priority patent/EP1237855B1/en
Priority to PCT/SE2000/002384 priority patent/WO2001040171A1/en
Priority to EEP200200278A priority patent/EE200200278A/en
Priority to AT00983618T priority patent/ATE261431T1/en
Priority to HU0203444A priority patent/HUP0203444A3/en
Priority to TR2004/01333T priority patent/TR200401333T4/en
Priority to AU20350/01A priority patent/AU773777B2/en
Priority to DE60008921T priority patent/DE60008921T2/en
Priority to MXPA02005327A priority patent/MXPA02005327A/en
Priority to NZ518925A priority patent/NZ518925A/en
Priority to ES00983618T priority patent/ES2215769T3/en
Priority to PL00357118A priority patent/PL357118A1/en
Priority to PT00983618T priority patent/PT1237855E/en
Priority to BR0016131-4A priority patent/BR0016131A/en
Priority to MYPI20005604A priority patent/MY135954A/en
Priority to CO00091767A priority patent/CO5271735A1/en
Priority to ARP000106382A priority patent/AR029412A1/en
Priority to ZA200203706A priority patent/ZA200203706B/en
Priority to IS6400A priority patent/IS6400A/en
Priority to NO20022598A priority patent/NO20022598L/en
Priority to HK03101132A priority patent/HK1048980A1/en

Links

Landscapes

  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

The present invention relates to a novel crystalline form of the compound (S)-2-ethoxy-3-(4-(2-(4-methanesulfony-loxyphenyl}ethoxy)phenyl] propanoic acid, shown by formula (I), or a pharmaceutically-acceptable salt thereof, and solvates thereof. The invention also concerns methods of treating one or more metabolic disease conditions, particularly those associated with Insulin Resistance Syndrome, and the use of a crystalline form of the compound, or a pharmaceutically-acceptable salt thereof, or a solvate thereof, in the manufacture of a medicament for use in one or more of said conditions. The invention further concerns pharmaceutical compositions containing a crystalline form of the compound, or a pharmaceutically-acceptable salt thereof, or a solvate thereof, as active ingredient, as well as processes for the manufacture of a crystalline form of the compound, or a pharmaceutically-acceptable salt thereof, or a solvate thereof. (I)
SE9904416A 1999-12-03 1999-12-03 Crystalline form SE9904416D0 (en)

Priority Applications (34)

Application Number Priority Date Filing Date Title
SE9904416A SE9904416D0 (en) 1999-12-03 1999-12-03 Crystalline form
BR0016131-4A BR0016131A (en) 1999-12-03 2000-11-29 Crystalline form, pharmaceutical formulation, use of a crystalline form, use of a substance, methods for the treatment or prophylaxis of, conditions associated with reduced insulin sensitivity, and delipidemia, type 2 diabetes mellitus, hyperglycemia, hyperinsulinemia, hypertension and / or abdominal obesity, and, process for the preparation of a crystalline form of a compound of formula i
AT00983618T ATE261431T1 (en) 1999-12-03 2000-11-29 CRYSTALLINE FORM OF (S)-2-ETHOXY-3-4-(2-4- METHANESULFONYLOXYPHENYL-ETHOXY)PHENYL)PROPANE ACID E
TR2004/01333T TR200401333T4 (en) 1999-12-03 2000-11-29 Crystalline Form of (S) -2 Ethoxy -3-4- (2-4-Methanesulfonyloxyphenyl Ethoxy) Phenyl] Propanoic Acid
CNB008163804A CN1198799C (en) 1999-12-03 2000-11-29 Crystalline form of (S)-2-ethoxy-3-[4-(2-{4-methane sulfonyloxy phenyl} ethoxy) phenyl] propanoic acid
HU0203444A HUP0203444A3 (en) 1999-12-03 2000-11-29 Crystalline form of (s)-2 ethoxy-3-[4-(2-{4-methanesulfonyloxyphenyl}ethoxy)phenyl]propanoic acid, process for its preparation, pharmaceutical composition containing it and use thereof
UA2002053990A UA75582C2 (en) 1999-12-03 2000-11-29 Crystalline form of (s)-2 ethoxy-3-[4-(2-{4-methanesulfonyloxyphenyl} ethoxy] phenyl) propanoic acid, process for preparation thereof and use in medicine (variants)
KR1020027007071A KR20030029040A (en) 1999-12-03 2000-11-29 Crystalline Form of (S)―2―ethoxy―3―〔4―(2―{4―methanesulfonyloxyphenyl}ethoxy)phenyl〕 propanoic acid
JP2001541858A JP2003515582A (en) 1999-12-03 2000-11-29 Crystal form of (S) -2-ethoxy-3- [4- (2- {4-methanesulfonyloxyphenyl} ethoxy) phenyl] propionic acid
SK765-2002A SK7652002A3 (en) 1999-12-03 2000-11-29 Crystalline form of (s)-2-ethoxy-3-[4-(2-{4- methanesulfonyloxyphenyl} ethoxy) phenyl] propanoic acid
CZ20021902A CZ20021902A3 (en) 1999-12-03 2000-11-29 Crystalline form of (S)-2-ethoxy-3-[4-(2-{4-methanesulfonyloxyphenyl}ethoxy)phenyl]propanoic acid
SI200030350T SI1237855T1 (en) 1999-12-03 2000-11-29 Crystalline form of (s)-2 ethoxy-3- 4-(2- 4-methanesulfonyloxyphenyl ethoxy) phenyl) propanoic acid
DK00983618T DK1237855T3 (en) 1999-12-03 2000-11-29 Crystalline form of (S) -2-ethoxy-3- [4- (2- (4-methanesulfonyloxyphenyl) ethoxy) phenyl] propanoic acid
RU2002113450/04A RU2268880C2 (en) 1999-12-03 2000-11-29 Crystalline form of (s)-2-ethoxy-3-[4-(2-{4-methanesulfonyloxyphenyl}ethoxy)phenyl]propanoic acid
EP00983618A EP1237855B1 (en) 1999-12-03 2000-11-29 Crystalline form of (s)-2 ethoxy-3- 4-(2- 4-methanesulfonyloxyphenyl ethoxy) phenyl] propanoic acid
AU20350/01A AU773777B2 (en) 1999-12-03 2000-11-29 Crystalline form of (S)-2 ethoxy-3-(4-(2-(4-methanesulfonyloxyphenyl) ethoxy) phenyl) propanoic acid
EEP200200278A EE200200278A (en) 1999-12-03 2000-11-29 Crystalline form of (S) -2-ethoxy-3- [4- (2- {4-methanesulfonyloxyphenyl} ethoxy) phenyl] propanoic acid
US10/148,821 US6531622B1 (en) 1999-12-03 2000-11-29 Crytalline form of (s)-2 ethoxy -3-[4-(2-{4- methanesulfonyloxyphenyl} ethoxy)phenyl]propanoic acid
IL14957700A IL149577A0 (en) 1999-12-03 2000-11-29 Crystalline form of (s)-2 ethoxy-3-[4-(2-{4-methanesulfonyloxyphenyl}ethoxy)phenyl] propanoic acid
CA002392038A CA2392038A1 (en) 1999-12-03 2000-11-29 Crystalline form of (s)-2 ethoxy-3-[4-(2-{4-methanesulfonyloxyphenyl} ethoxy) phenyl] propanoic acid
PCT/SE2000/002384 WO2001040171A1 (en) 1999-12-03 2000-11-29 Crystalline form of (s)-2 ethoxy-3-[4-(2-{4-methanesulfonyloxyphenyl} ethoxy) phenyl] propanoic acid
DE60008921T DE60008921T2 (en) 1999-12-03 2000-11-29 CRYSTALLINE FORM OF (S) -2-ETHOXY-3-4- (2-4-METHANSULFONYLOXYPHENYL-ETHOXY) PHENYL] PROPANIC ACID
MXPA02005327A MXPA02005327A (en) 1999-12-03 2000-11-29 CRYSTALLINE FORM OF (S) 2 ETHOXY 3 [4 (2 lcub;4 METHANESULFONYLOXYPHENYLrcub; ETHOXY) PHENYL] PROPANOIC ACID.
NZ518925A NZ518925A (en) 1999-12-03 2000-11-29 Crystalline form of (S)-2 ethoxy-3-[4-(2-{4-methanesulfonyloxyphenyl} ethoxy) phenyl] propanoic acid
ES00983618T ES2215769T3 (en) 1999-12-03 2000-11-29 CRYSTALLINE FORM OF ACID (S) -2-ETOXI-3- (4- (2- (4-METHANOSULPHONYLOXYPHENYL) ETOXI) PHENYL) PROPANOIC.
PL00357118A PL357118A1 (en) 1999-12-03 2000-11-29 Crystalline form of (s)-2 ethoxy-3-[4-(2-{4-methanesulfonyloxyphenyl} ethoxy) phenyl] propanoic acid
PT00983618T PT1237855E (en) 1999-12-03 2000-11-29 (S) -2-ETOXY-3 - [4- (2- {4-METHOSULPHONYL-OXYPHENYL} ETHOXY) PHENYL] PROPANOIC CRYSTALLINE FORM
CO00091767A CO5271735A1 (en) 1999-12-03 2000-11-30 CRYSTAL FORM
MYPI20005604A MY135954A (en) 1999-12-03 2000-11-30 Crystalline form of (s)-ethoxy-3-4-(2-4-methanesulfonyloxyphenyl ethoxy) phenyl] propanoic acid
ARP000106382A AR029412A1 (en) 1999-12-03 2000-12-01 CRYSTAL FORM
ZA200203706A ZA200203706B (en) 1999-12-03 2002-05-09 Crystalline form of (S)-2ethoxy-3-[4-(2-4-methanesulfonyloxyphenyl} ethoxy)phenyl] propanoic acid.
IS6400A IS6400A (en) 1999-12-03 2002-05-28 Crystalline form (S) -2-ethoxy-3- [4- (2- {4-methanesulfonylphenyl} ethoxy) phenyl] propanoic acid
NO20022598A NO20022598L (en) 1999-12-03 2002-05-31 Crystalline form of (S) -2-ethoxy-3- [4- (2- {4- methanesulfonyloxyphenyl} -ethoxy) -phenyl] -propanoic acid
HK03101132A HK1048980A1 (en) 1999-12-03 2003-02-17 Crystalline form of (s)-2 ethoxy-3-4-(2-4-methanesulfonyloxyphenyl ethoxy) phenylÜ propanoic acid (s)-2-3-Ä4

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE9904416A SE9904416D0 (en) 1999-12-03 1999-12-03 Crystalline form

Publications (1)

Publication Number Publication Date
SE9904416D0 true SE9904416D0 (en) 1999-12-03

Family

ID=20417981

Family Applications (1)

Application Number Title Priority Date Filing Date
SE9904416A SE9904416D0 (en) 1999-12-03 1999-12-03 Crystalline form

Country Status (3)

Country Link
SE (1) SE9904416D0 (en)
UA (1) UA75582C2 (en)
ZA (1) ZA200203706B (en)

Also Published As

Publication number Publication date
ZA200203706B (en) 2003-10-29
UA75582C2 (en) 2006-05-15

Similar Documents

Publication Publication Date Title
MY135954A (en) Crystalline form of (s)-ethoxy-3-4-(2-4-methanesulfonyloxyphenyl ethoxy) phenyl] propanoic acid
SE9904413D0 (en) Comminuted form
SE0104334D0 (en) Therapeutic agents
RU2008129723A (en) CCR9 ACTIVITY INHIBITORS
WO2007082808A3 (en) Thiazoles as 11 beta-hsd1 inhibitors
EA200301216A1 (en) MULTICYCLIC HETEROARYLS SUBSTITUTED WITH QUINUCLIDINES FOR THE DISEASE TREATMENT
NO20071577L (en) Biphenyloxyacetic acid derivatives for the treatment of respiratory diseases
GEP20094605B (en) Pyrazole derivatives, compositions containing such compounds and methods of use thereof
NO20052914L (en) Therapeutic compounds
ATE442349T1 (en) DIACYLGLYCEROL ACYLTRANSFERASE INHIBITORS
SE0300010D0 (en) Novel Compounds
RU2008129641A (en) CCR9 ACTIVITY INHIBITORS
ATE450496T1 (en) COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS
EA200200489A1 (en) NEW COMPOUNDS OF BENZOTHIADIAZINE, METHOD OF THEIR PRODUCTION AND CONTAINING THEIR PHARMACEUTICAL COMPOSITIONS
ATE366107T1 (en) USE OF SULFODEHYDROABIETIC ACID TO TREAT INFLAMMATORY BOWEL DISEASE
RU2008129623A (en) CCR9 ACTIVITY INHIBITORS
HUP0402515A2 (en) Novel substituted n-[4-(1h-imidazol-1-yl)-2-fluorophenyl]-3-(trifluoromethyl)-1h-pyrazole-5-carboxamides as inhibitors of factor xa, their use and pharmaceutical compositions containing them
SE9904412D0 (en) Comminuted form
FR2865732B1 (en) HYDRAZID-TYPE COMPOUNDS AND THEIR USE IN PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF CARDIOVASCULAR DISEASES
SE0102057D0 (en) New Salts I
SE9901572D0 (en) New compounds
KR880001593A (en) 4- (aroylamino) piperidinebutanamide derivative
SE0104333D0 (en) Therapeutic agents
SE9904416D0 (en) Crystalline form
AR026704A1 (en) CRYSTAL FORM